Evidence map›Paper›PMID 42453757›Full record

ArticleIntestinal Failure (New York, N.Y.)

Use of vedolizumab in pediatric intestinal transplant rejection.

Shahira Ghobrial, Dimitrios Moris, Carolina Rumbo, Stuart S Kaufman, Gabriel Gondolesi, Dong Hyang Kwon, Yoshinori Takeda, Nada Yazigi, Udeme D Ekong, Thomas M Fishbein and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shahira GhobrialMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Dimitrios MorisMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Carolina RumboMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Stuart S KaufmanMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Gabriel GondolesiMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Dong Hyang KwonMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Yoshinori TakedaMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Nada YazigiMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Udeme D EkongMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Thomas M FishbeinMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Cal S MatsumotoMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Alexander KroemerMedStar Georgetown University Hospital, Washington, DC 20007, USA.
Khalid KhanMedStar Georgetown University Hospital, Washington, DC 20007, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Blockade of α4β7 integrin cell adhesion receptors on activated lymphocytes with the monoclonal antibody vedolizumab (VDZ) is efficacious in treatment of inflammatory bowel disease and most probably intestinal graft versus host disease (GVHD) after stem cell transplantation. Recently, there have been reports indicating that VDZ may be similarly effective in the treatment of acute rejection after intestinal transplantation (ITx). Herein, we report 3 additional cases. Case Presentation: Mucosal recovery was achieved in 2 of the 3 patients, within 6 days after the first VDZ dose in one and with early restoration of enteral nutrition in the other. There was no response to VDZ in the third case. Complications potentially attributable to VDZ included graft pneumatosis and late-onset histoplasmosis. Conclusions: These cases describe both benefits and limitations of VDZ in ITx. They also suggest that VDZ may be useful in post-ITx rejection prophylaxis and for the treatment of intestinal GVHD.

Indexed as

Acute rejectionIntegrinsIntestinal transplantVedolizumab

Identifiers

PMID42453757
PMCPMC13365910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.